Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia Clinical Trial
— DIALOGOfficial title:
A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib
| Verified date | March 2021 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
| Status | Completed |
| Enrollment | 59 |
| Est. completion date | August 28, 2020 |
| Est. primary completion date | June 1, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 17 Years |
| Eligibility | Key Inclusion Criteria: - Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib - Karnofsky = 50% for patients > 10 years of age and Lansky = 50 for patients = 10 years of age - Adequate renal, hepatic and pancreatic function - Potassium, magnesium, phosphorus and total calcium values = LLN (lower limit of normal) - Written informed consent Key Exclusion Criteria: - Treatment with strong CYP3A4 inhibitors or inducers - Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval - Acute or chronic liver, pancreatic or severe renal disease - History of pancreatitis or chronic pancreatitis. - Impaired cardiac function - No evidence of active graft vs host and <3mo since Stem Cell Transplant - Total body irradiation (TBI) or craniospinal radiation therapy <6months - Hypersensitivity to the active ingredient or any of the excipients including lactose. - the criteria regarding pregnancy and contraception - Active or systemic bacterial, fungal, or viral infection - known Hepatitis B, Hepatitis C, or HIV infection |
| Country | Name | City | State |
|---|---|---|---|
| France | Novartis Investigative Site | Bordeaux | Aquitaine |
| France | Novartis Investigative Site | Lille | |
| France | Novartis Investigative Site | Paris Cedex | |
| France | Novartis Investigative Site | Poitiers | |
| Hungary | Novartis Investigative Site | Budapest | |
| Italy | Novartis Investigative Site | Genova | GE |
| Italy | Novartis Investigative Site | Monza | MB |
| Italy | Novartis Investigative Site | Padova | PD |
| Italy | Novartis Investigative Site | Torino | TO |
| Japan | Novartis Investigative Site | Saitama | |
| Japan | Novartis Investigative Site | Sakyo Ku | Kyoto |
| Japan | Novartis Investigative Site | Shinjuku-ku | Tokyo |
| Japan | Novartis Investigative Site | Shizuoka | |
| Japan | Novartis Investigative Site | Yokohama-city | Kanagawa |
| Korea, Republic of | Novartis Investigative Site | Seoul | |
| Korea, Republic of | Novartis Investigative Site | Seoul | |
| Malaysia | Novartis Investigative Site | Kuala Lumpur | |
| Netherlands | Novartis Investigative Site | Rotterdam | |
| Russian Federation | Novartis Investigative Site | Moscow | |
| Spain | Novartis Investigative Site | Madrid | |
| Thailand | Novartis Investigative Site | Bangkok | |
| Thailand | Novartis Investigative Site | Bangkok | |
| Thailand | Novartis Investigative Site | Muang | Chiangmai |
| Turkey | Novartis Investigative Site | Istanbul | |
| United Kingdom | Novartis Investigative Site | Bristol | |
| United Kingdom | Novartis Investigative Site | Sutton | Surrey |
| United States | Johns Hopkins Oncology Center ORA | Baltimore | Maryland |
| United States | UNC Chapel Hill | Chapel Hill | North Carolina |
| United States | Nationwide Childrens Hospital | Columbus | Ohio |
| United States | University of Texas Southwestern Medical Center Oncology | Dallas | Texas |
| United States | Cook Children's Medical Center Oncology | Fort Worth | Texas |
| United States | Loma Linda University Cancer Center | Loma Linda | California |
| United States | Nemours Childrens Hospital | Orlando | Florida |
| United States | Lucile Salter Packard Children's Hospital at Stanford | Palo Alto | California |
| United States | Seattle Childrens Hospital | Seattle | Washington |
| United States | St. Mary's Hospital | West Palm Beach | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
United States, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Russian Federation, Spain, Thailand, Turkey, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Long Term Effect of Nilotinib on Bone Metabolism | The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib. | Cycle 66 | |
| Primary | Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib | MMR is defined as = 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to = 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit. | 6 cycles | |
| Primary | MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients | MMR is defined as = 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to = 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included. | 12 cycles | |
| Primary | Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients | Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit. | 12 cycles | |
| Secondary | MMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib | Major molecular response (MMR) was defined as BCR-ABL/ABL % = 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample. | By 3, 6, 9 , 12, 24, 36, 48, 66 cycles ( 1 cycle = 28 days) | |
| Secondary | MMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients | Major molecular response (MMR) was defined as BCR-ABL/ABL % = 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample. | by 3, 6, 9, 12, 24, 36, 48, 66 cycles (1 cycle = 28 days) | |
| Secondary | Best BCR-ABL Ratio Categories for Resistant/Intolerant Ph+ CML - Overall | MMR is defined as = 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to = 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: > 0.0032 to = 0.01% is equal to a log reduction category of >= 4 to <4.5 -log reduction (MR4); BCR-ABL ratio by percentage: <=0.0032% is equal to a log reduction category of >= 4.5-log reduction (MMR4.5) | up to 66 cycles (1 cycle = 28 days) | |
| Secondary | Best BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall | MMR is defined as = 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to = 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: > 0.0032 to = 0.01% is equal to a log reduction category of >= 4 to <4.5 -log reduction (MR4); BCR-ABL ratio by percentage: <=0.0032% is equal to a log reduction category of >= 4.5-log reduction (MMR4.5) | up to 66 cycles (1 cycle = 28 days) | |
| Secondary | Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR | Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR. | From first dosing to the first MMR within 66 cycles period | |
| Secondary | Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR | Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR. | From first dosing to the first MMR within 66 cycles period | |
| Secondary | Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR | Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date. | from MMR until confirmed loss of MMR (Assessed up to 66 cycles) | |
| Secondary | Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMR | Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date. | from MMR until confirmed loss of MMR (Assessed up to 66 cycles)es) | |
| Secondary | Best Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall | Complete cytogenetic response (CCyR) - 0% Ph+ metaphases Partial cytogenetic response (PCyR) - >0 to 35% Ph+ metaphases Minor cytogenetic response (mCyR) - >35 to 65% Ph+ metaphases Minimal - >65 to 95% Ph+ metaphases None - >95 to 100% Ph+ metaphases Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses. |
up to 66 cycles | |
| Secondary | Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall | Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - >95 to 100% Ph+ metaphases | up to 66 cycles | |
| Secondary | Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients | Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included. | From first dosing to the first CCyR up to 66 cycles | |
| Secondary | Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients | Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included. | From first dosing to the first CCyR up to 66 cycles | |
| Secondary | Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients | Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included. | From CCyR to loss of CCyR up to 66 cycles | |
| Secondary | Best Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients | Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses. | 6, 12, 18, 24, 36, 48, 66 cycles | |
| Secondary | Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients | Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses. | up to 66 cycles | |
| Secondary | Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients | Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses. | up to 66 cycles | |
| Secondary | Best Complete Hematological Response (CHR) by Time Point | Complete Hematological Response (CHR) was defined as WBC count <10×109/L platelet count <450×109/L basophils <5% no blasts and promyelocytes in peripheral blood myelocytes+metamyelocytes <5% in peripheral blood no evidence of extramedullary disease, including spleen and liver Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP |
cycle 3, 6, 9, 12, 18, 24, 36, 48, 66 | |
| Secondary | Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients | Complete Hematological Response (CHR) was defined as WBC count <10×109/L platelet count <450×109/L basophils <5% no blasts and promyelocytes in peripheral blood myelocytes+metamyelocytes <5% in peripheral blood no evidence of extramedullary disease, including spleen and liver Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP |
from first dosing to CHR, UP TO 66 CYCLES | |
| Secondary | Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients | Complete Hematological Response (CHR) was defined as WBC count <10×109/L platelet count <450×109/L basophils <5% no blasts and promyelocytes in peripheral blood myelocytes+metamyelocytes <5% in peripheral blood no evidence of extramedullary disease, including spleen and liver Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP |
from first dosing to CHR, UP TO 66 CYCLES | |
| Secondary | Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates | Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier. | From first dosing to the disease progression within 66 cycles | |
| Secondary | Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients | Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment) | From first dosing to the disease progression or death up to 66 cycles | |
| Secondary | Event Free Survival in Newly Diagnosed CML-CP Patients | Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment) | From first dosing to the disease progression or death up to 66 cycles | |
| Secondary | Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates | Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up. | from first dosing to death up to 66 cycles | |
| Secondary | Overall Survival (OS) in Newly Diagnosed CML-CP Patients | Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up. | from first dosing to death up to 66 cycles | |
| Secondary | Pharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle | BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as = 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to = 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR. | By 3, 6, 9, 12, 18, 24, 36, 48, 66 cycles | |
| Secondary | Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients | PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early. | Cycle 1 Day 8 | |
| Secondary | Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients | PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early. | Cycle 1 Day 8 | |
| Secondary | Growth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort | To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value. | from first dosing to 66 cycles | |
| Secondary | Acceptability (Including Palatability) of Dose Forms Used After First Dose, Cycle 1 and Cycle 12 Study Drug Formulation | Acceptability of the study drug was evaluated from a questionnaire completed by patients, with the help from parents or caregivers at visits. The Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration). |
up to Cycle 12 | |
| Secondary | Mutational Assessment of BCR-ABL | Emerging signs of resistance to nilotinib | up to 66 cycles |